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Summary
Hearing loss involves both genetic and environmental
factors. A mutation (A1555G) in the mtDNA has been
associated with aminoglycoside-induced and nonsyn-
dromic sensorineural deafness. The pathological signif-
icance of this mutation in Caucasoid families has not
been established, and its relationship with antibiotic
treatment is not well understood. We studied 70 Spanish
families with sensorineural deafness (36 congenital and
34 late onset) for the mtDNA A1555G mutation. The
A1555G mutation was found in 19 families with ma-
ternally transmitted deafness but not in the other 51
families or in 200 control subjects. In 12 families all the
patients with the A1555G mutation who received ami-
noglycosides became deaf, representing 30.3% of the
deaf patients in these families. None of the deaf patients
from seven other families received aminoglycosides.
Overall, only 17.7% of the patients with deafness and
the A1555G mutation had been treated with aminog-
lycosides. The age at onset of deafness was lower (me-
dian age 5 years, range 1–52 years) in those treated with
aminoglycosides than in those who did not receive an-
tibiotics (median age 20 years, range 1–65 years) (P !
). The mtDNA of these families belongs to haplo-.001
types common in Europeans. These data indicate that
the A1555G mutation accounts for a large proportion
of the Spanish families with late-onset sensorineural
deafness, that the A1555G mutation has an age-de-
pendent penetrance for deafness (enhanced by treatment
with aminoglycosides), and that mtDNA backgrounds
probably do not play a major role in disease expression.
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Introduction
Hearing loss affects ∼1/1,000 infants, 5% of people !45
years of age, and 30% of subjects 170 years of age
(Nance and Sweeney 1975; Cohen and Gorlin 1995; Van
Camp et al. 1997). In ∼50% of cases of profound deaf-
ness in childhood there is probably a genetic predispo-
sition (Brown 1969; Morton 1991). In adult patients,
presbycusis is the most common cause of hearing loss
and also involves genetic and hereditary factors (Nadol
1993; Gorlin 1995). Hereditary deafness is a heteroge-
neous group of disorders with different patterns of in-
heritance (18% autosomal dominant, 80% autosomal
recessive, and ∼2% X linked) (Konigsmark 1969; Cohen
and Gorlin 1995). Hearing loss of genetic origin can be
conductive or sensorineural and can form part of a syn-
drome, with other clinical abnormalities (30%), or it
may be the sole clinical symptom (70%) (Cohen and
Gorlin 1995).
The number of genes involved in deafness is unknown
but is estimated to be several hundred (Steel and Brown
1994; Petit 1996). The genetic bases of some syndromic
forms of deafness have been discovered during recent
years, and they include some of the genes that cause
Waardenburg syndrome (Tassabehji et al. 1992, 1994),
Norrie disease (Berger et al. 1992), and Usher syndrome
(Weil et al. 1995). Nonsyndromic sensorineural hearing
loss is also genetically determined, and linkage studies
have localized 130 genes involved in autosomal domi-
nant, autosomal recessive, and X-linked hearing loss
(Petit 1996; Van Camp et al. 1997). Two genes involved
in nonsyndromic sensorineural deafness (POU3F4 at
Xq21.1 and MYOVIIA at 11q13.5) already have been
identified (Guilford et al. 1994; de Kok et al. 1995).
Positional cloning and candidate-gene approaches are
being undertaken to identify the other genes. Recently,
mutations in the connexin-26 (GJB2) gene (Kelsell et al.
1997; Zelante et al. 1997) and in the MYOVIIA gene
(Liu et al. 1997; Weil et al. 1997) have been detected in
autosomal recessive sensorineural deafness.
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It is likely that the interaction of genes with environ-
mental factors plays an important role in the develop-
ment of deafness, especially for late-onset cases. Most
ototoxic substances are found in high concentrations in
the inner ear and cause hearing loss by damaging the
cochlea, in particular the auditory hair cells and the stria
vascularis (Nadol 1993). Aminoglycoside antibiotics are
well known for their ototoxicity, which affects ∼25% of
the patients who receive these drugs (Hawkins 1976).
Recent work has shown that aminoglycosides produce
an enhancement of the N-methyl-D-aspartate (NMDA)–
receptor activity, resulting in hair-cell death through an
excitotoxic mechanism (Basile et al. 1996).
Some sensorineural nonsyndromic and antibiotic-in-
duced hearing losses show a mitochondrial mode of in-
heritance, being transmitted only through females. The
relationship between deafness and mitochondrial mu-
tations has been defined for mitochondrial syndromes
associated with hearing impairment and also for non-
syndromic sensorineural deafness.
The A1555G mutation in the mitochondrial 12S
rRNA has been associated with aminoglycoside-induced
and nonsyndromic sensorineural deafness (Prezant et al.
1993). The pathological significance of this mutation in
congenital and late-onset–deafness families has not been
established, and its relationship with antibiotic treat-
ment is not well understood. To investigate both the role
played by the A1555G mutation in hereditary deafness
and its relationship with aminoglycoside treatment, we
have analyzed 70 unrelated and unselected Spanish fam-
ilies suffering from sensorineural hearing loss. We have
found the A1555G mutation in the 19 pedigrees with
progressive and maternally transmitted deafness. The
study revealed that the A1555G mutation is the most
common cause of late-onset familial sensorineural deaf-
ness in our families and that it originated independently
in several lineages. Moreover, the study shows that ami-
noglycosides accelerate the development of deafness and
that factors other than aminoglycosides probably con-




We collected 70 Spanish families with severe senso-
rineural inherited hearing loss. The limiting criteria used
in the selection of the families were that the deafness
(congenital or progressive) had to be nonsyndromic and
that the family had to have at least two affected mem-
bers. Forty-two families were from clinical centers, and
28 were obtained through advertisements in the public
media. The collection and analysis of samples was per-
formed in accordance with the approved ethics rules for
genetic studies. Informed consent for analysis was ob-
tained from all members of the families that participated
in the study. Families with deafness were classified as
autosomal dominant, autosomal recessive, X linked, or
mitochondrial (only maternal transmission), in accor-
dance with the patterns of transmission of deafness. Ped-
igree analyses showed a segregation pattern of deafness
consistent with maternal transmission, for 19 of the 70
families. For these 19 families the information regarding
the onset and progression of hearing loss, the history of
treatment with antibiotics, and the presence of other
factors involved in deafness was collected from at least
one member from each nuclear family, which implies
several members from each of the pedigrees. For all the
families with children, the information was ascertained
from the parents (mainly the mother). For adult affected
patients, the information was obtained from at least one
relative from the same generation. We screened for the
A1555G mutation in the index cases from the 70 deaf-
ness families and in all the available samples (58 affected
and 44 at risk) from the 19 families consistent with
maternal inheritance. The controls for the molecular
analysis of the A1555G mutation were 200 normal sub-
jects from the general population, who were originally
from different regions of Spain. The controls for hap-
lotype and phylogenetic analyses were 237 subjects from
several western European countries, including Spain.
mtDNA Studies
The A1555G mutation was analyzed by amplification
of mtDNA, by PCR using 50 ng of DNA and 10 pmol
of each primer (5′-GCT CAG CCT ATA TAC CGC CAT
CTT CAG CAA-3′ [sense] and 5′-TTT CCA GTA CAC
TTA CCA TGT TAC GAC TGG-3′ [antisense]), by di-
gestion of the amplified 339-bp fragment, with the re-
striction enzyme HaeIII, and by electrophoresis on a 3%
agarose gel. The antisense oligonucleotide was modified
by changing the penultimate nucleotide from T to G
(underlined), which created the restriction site HaeIII
(GGCC/CCGG) if the G at position 1555 of the 12S
rRNA was present in the patient. The PCR product con-
tains another HaeIII site, which serves as a control of
enzyme digestion. Normal subjects have two fragments,
of 216 bp and 123 bp, and the affected patients have
fragments of 216 bp, 93 bp, and 30 bp, owing to the
creation of a HaeIII site by the A1555G mutation. The
presence of the A1555G mutation was confirmed by
sequencing of the PCR products, with a 373A DNA
sequencer and the cycle dye terminator DNA sequencing
kit (Applied Biosystems). Two point mutations in the
tRNA(Ser), at nt 7445 and 7472, and possible deletions
or duplications of the mtDNA (Reid et al. 1994; Tiranti
et al. 1995) also were studied.
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Haplotype and Phylogenetic Analyses
The entire mtDNA of 10 patients from 10 unrelated
pedigrees (S1–S10) was amplified in nine overlapping
fragments, by PCR, as described elsewhere (Torroni et
al. 1996). Each of the nine PCR segments was digested
with 14 restriction endonucleases (AluI, AvaII, BamHI,
DdeI, HaeII, HaeIII, HhaI, HincII, HinfI, HpaI, MspI,
MboI, RsaI, and TaqI). All subjects were screened for
several European-specific polymorphisms, including a
BstNI site at nt 13704, an AccI site at nt 15254, two
NlaIII sites, at nt 4216 and 4577, a BfaI site at nt 4917,
and an A/G polymorphism at nt 12308 in the tRNA(Leu)
gene (Torroni et al. 1997). Restriction fragments were
resolved by electrophoresis on NuSieve plus SeaKem
agarose (FMC BioProducts) gels. This procedure allows
both the screening of ∼20% of the sequence variation
in each mtDNA and the definition of haplotypes.
The phylogenetic relationships between the haplo-
types of the patients and those found in 237 European
control subjects were inferred by parsimony analysis.
The dendrograms were rooted by use of the African
haplotype AF71 (the so-called African outgroup), which
is a member of the African-specific haplogroup L and
already has been used as an outgroup (Torroni et al.
1994). Maximum-parsimony trees were generated by
random addition of sequences, by use of the “Tree Bi-
section and Reconnection” algorithm (phylogenetic
analysis using parsimony) (Swofford 1993). The analysis
was terminated at 1,000 trees, after 140 replications.
Statistical Analyses
Log-transformed ages at onset of deafness were com-
pared between the group of deaf patients who received
aminoglycosides and (a) the group of relatives with deaf-
ness and the A1555G mutation who were not treated
with antibiotics, by use of the two-way (relation and
treatment with aminoglycosides) analysis of variance,
and (b) the entire group of deaf but untreated patients,
by use of Student’s t-test for independent data. x2 Tests
were used to compare differences between groups of pa-
tients and at-risk individuals and also between the deaf-
ness families collected from clinical centers and those
ascertained through advertisements in the public media.
The statistics package SPSS 6.1.3 was used for calcu-
lations. The penetrance of the mtDNA A1555G muta-
tion was calculated as the complementary function of
the cumulative proportion of survival. This was calcu-
lated for the A1555G patients treated with aminogly-
cosides, for those untreated, and for all the subjects with
the A1555G mutation.
Results
Maternally Transmitted Progressive Sensorineural
Deafness
Among the 70 families, 36 had congenital deafness,
and in 34 the hearing loss was progressive. Nineteen
(27.1%) of the 70 pedigrees showed a segregation pat-
tern of deafness that was consistent/compatible with ma-
ternal transmission, whereas 40 (57.1%) were recessive,
10 (14.3%) were dominant, and 1 (1.4%) was X linked.
There were differences between the deafness families col-
lected from clinical centers and those ascertained
through advertisements in the public media, with a larger
number of congenital families from the clinical centers
( ) and a larger number of mitochondrial casesP ! .02
from advertisements in the media ( ). The 19P ! .001
families with maternal transmission included a total of
214 deaf patients and 215 subjects (the unaffected chil-
dren and siblings of a woman with a mitochondrial mu-
tation) “at risk” of developing deafness (fig. 1). The 19
families were from different regions of Spain, and there
was no consanguinity.
The affected subjects of the 19 families with mater-
nally inherited deafness presented with bilateral and sen-
sorineural hearing loss as the sole clinical symptom.
Most of the patients had late-onset/progressive deafness,
but in eight patients, from six different families, deafness
started at !2 years of age. There was a wide variability
in the age at onset of deafness within each family. The
age at onset of deafness was within the range of 1–65
years (mean SD  ) and was !40 years20.7  18.6
in 82.5% of the cases. Audiometric studies of 20 affected
individuals showed severe to profound sensorineural bi-
lateral deafness at 40 dB, at 250 Hz, and at 110 dB, at
8,000 Hz. No other clinical alterations, including CNS
or neuromuscular problems, cardiomiopathy, or diabe-
tes, were observed in the patients. Biochemical studies
of 12 deaf patients failed to detect hyperglycemia or
other abnormalities.
Familial Sensorineural Deafness and Treatment with
Aminoglycosides
In 12 (52.6%; S2, S4, S6–S11, S14, S16, S18, and
S19) of the 19 families with maternally inherited deaf-
ness, all the patients that received aminoglycosides be-
came deaf (one to seven patients per family), but these
patients represent only 30.3% of the affected family
members (fig. 1). The relationship between deafness and
treatment with aminoglycosides was absolute in only
three pedigrees (S2, S7, and S8). In families S4, S11, and
S14, 30%–50% of the deaf patients received antibiotics.
However, in six other families (S6, S9, S10, S16, S18,
and S19) only 1–3 patients with deafness, of 4–26, re-
ceived aminoglycosides. There were several cases in
Figure 1 Nineteen Spanish pedigrees affected by maternally inherited deafness and harboring the A1555G mutation in the 12S rRNA
gene of the mtDNA. A, Twelve pedigrees with deafness related to treatment with aminoglycoside antibiotics, for at least one affected subject.
B, Seven pedigrees with deafness not related to aminoglycoside treatment. Blackened symbols indicate patients who have developed sensorineural
deafness and were not treated with aminoglycosides. Gray-shaded symbols indicate deaf patients who have received antibiotic treatment. An
asterisk (*) indicates the patients from whom DNA samples were obtained. A number beneath a symbol indicates the number of descendants.
The A1555G mutation was found in all the deaf patients analyzed and in their maternal relatives.
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which hearing loss developed before the clinical intro-
duction of aminoglycosides. In family S4 patient I-1 de-
veloped deafness at 20 years of age (in 1910), and in
family S9 two patients (I-1 and II-1) became deaf in 1916
and 1936, respectively. Finally, in seven families (S1, S3,
S5, S12, S13, S15, and S17; 5–23 deaf patients/family)
there was no record of aminoglycoside administration.
Mitochondrial A1555G Mutation in Progressive
Deafness
An adenine-to-guanine transition at nt 1555 of the
mtDNA (the A1555G mutation) (Prezant et al. 1993) in
the 12S rRNA gene was found in homoplasmia in all
the subjects (102 patients) analyzed from the 19 families
with maternally transmitted deafness (fig. 2). The
A1555G mutation was not found in 200 control subjects
or in the index patients from the 51 families with a
Mendelian pattern of inheritance of deafness. Deafness
was reported in 214 (49.9%) of the 429 patients who
were expected to have received the A1555G mutation
from their A1555G-positive mothers. A previously un-
known nucleotide change in the mtDNA (CrT transi-
tion at nt 1537 of the 12S rRNA) was detected in family
S4 (fig. 2). Since this change eliminates a restriction site
for the enzymeNsiI, digestion with this enzyme was used
to study the other affected families and the normal sub-
jects. The change was present in homoplasmia in all
maternally related family members from family S4 and
was not found in the other families or in 50 normal
subjects.
Age at Onset and Penetrance of the A1555G Mutation
The age at onset of deafness in the patients treated
with aminoglycosides was lower (mean  SD 
years, median 5 years, range 1–52 years)11.1  12.1
than in those who did not receive antibiotics, when either
the patients from all the families (mean  SD 
years, median 16 years, range 1–65 years)21.2  17.6
( ; ) or only those from the families witht  2.84 P  .006
a record of exposure to aminoglycosides (mean  SD
 years, median 20 years, range 1–6524.8  17.4
years) ( ; ) were considered. The prob-F  21.2 P ! .001
abilities that an individual with the A1555G mutation
develops hearing loss by a certain age are shown in figure
3. The probabilities of deafness at 30 years of age are
96.5% in the treated group and 39.9% in the untreated
group.
One hundred thirty-seven at-risk patients (with the
A1555G mutation) from the families with aminoglyco-
side treatment (age range 1–84 years, mean  SD 
years) and 78 at-risk subjects from the32.3  21.3
families without a record of aminoglycoside treatment
(age range 1–80 years, mean  SD  )31.0  22.2
were asymptomatic at the time of the study or did not
develop deafness during their lifetime. Both the similar
proportion of deaf patients (47.1% with antibiotic treat-
ment and 54.1% without), with respect to the at-risk
subjects, in the two groups of families and the similar
mean age of the at-risk subjects in the two groups dem-
onstrate the strong role of the A1555G mutation in caus-
ing deafness, regardless of treatment with
aminoglycosides.
Phylogenetic Analysis of mtDNAs with the A1555G
Mutation
The mtDNA haplotypes for 10 unrelated patients be-
longing to families S1–S10 were determined. Haplotype
analysis revealed that these subjects harbored five dif-
ferent haplotypes described in Europeans (haplotypes 1,
2, 64, 109, and 123; fig. 4). Haplotypes 1, 2, and 64
are members of haplogroup H (Torroni et al. 1994) and
were present in eight families (S2, S3, and S5–S10) with
the A1555G mutation. Haplogroup H is the most com-
mon in western Europeans and reaches a frequency of
150% on the Iberian peninsula. Family S4 belongs to
haplogroup V, which is common on the Iberian penin-
sula, with a frequency of 20%. Both haplogroup H and
haplogroup V are European specific (Torroni et al.
1996). Finally, the haplotype observed in family S1 be-
longs to haplogroup L, which is African specific but not
uncommon in some southern European populations
(Spanish and southern Italian) (Torroni et al. 1994; Chen
et al. 1995). The parsimony tree of the mtDNA hap-
lotypes in the 10 sensorineural deafness patients is
shown in figure 4. This maximum-parsimony tree in-
cludes the five haplotypes observed in the patients and
those described elsewhere in 237 European controls. The
length of this tree is 374 steps, and it has consistency
and retention indices of .837 and .904, respectively.
Discussion
Common progressive (late-onset) deafness probably is
due to the combined action of mutations in susceptibility
genes (mitochondrial or nuclear) and environmental fac-
tors. Unfortunately, the link between gene abnormalities
and environmental influences in causing disease is still
poorly understood. We have detected the mitochondrial
A1555G mutation in 19 Spanish pedigrees (27.1% of
the total families studied) affected with progressive sen-
sorineural deafness. This mutation previously had been
reported only in a few families, either in combination
with aminoglycoside treatment (two Chinese [Prezant et
al. 1993], three Japanese [Hutchin et al. 1993], and two
Mongolian [Pandya et al. 1997] pedigrees) or in the
absence of antibiotic treatment (one Arab-Israeli pedi-
gree [Prezant et al. 1993] and one Zairean pedigree
[Matthijs et al. 1996]). More recently, it also has been
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Figure 2 A, Identification of the A1555G mutation and the nu-
cleotide change 1537T, in the 12S rRNA of the mtDNA. Top, Partial
sequence of the 12S rRNA gene, showing the 1555 ArG transition,
with the T at nt 1537, in one affected member (III-1) of family S4.
Bottom, Partial sequence showing the common C at nt 1537 and the
A1555G mutation, in a deaf patient (II-1) from family S2. The anti-
sense chromatograms are shown. B, Detection of the mtDNA A1555G
mutation in patients affected by maternally transmitted sensorineural
deafness. The analysis of the A1555G mutation was performed by
PCR amplification of a segment of the mitochondrial 12S rRNA gene
and by digestion with the restriction enzyme HaeIII. Lane M, Molec-
ular-weight marker. Lanes 1 and 10, Undigested control samples. Lanes
2 and 9, Digested control samples. Lanes 3–8, Index cases of families
S1–S6. The digested samples from control subjects have two fragments,
of 216 bp and 123 bp. The samples from affected patients have frag-
ments of 216 bp, 93 bp, and 30 bp, owing to the creation of a HaeIII
site by the A1555G mutation.
Figure 3 Graph of the probability that an individual possessing
the mtDNA A1555G mutation will develop hearing loss by a certain
age. The patients were grouped into those treated with aminoglyco-
sides, those untreated, and the total number of patients. The curves
represent the complementary function of the cumulative proportion
of survival. This allows estimation of the age-dependent penetrance
of the A1555G mutation. The median time to deafness was 5.63 years
for the treated group, 40.99 years for the untreated group, and 30.83
years for the total.
detected in two Spanish families (El-Schahawi et al.
1997) and in five Japanese families, with several subjects
having progressive deafness without treatment with ami-
noglycosides (Usami et al. 1997). The phylogenetic anal-
ysis of the mtDNA haplotypes that was performed here
revealed that the A1555G mutation in the Spanish fam-
ilies is the product of at least five independent mutational
events. Because 6 of the 10 pedigrees harbored the most
common European haplotype (haplotype 2), it is also
likely that at least some of the A1555G mutations in
haplotype 2 represent independent mutational events
rather than a single mutational event transmitted, by
descent, to the 6 pedigrees.
The detection of the mutation in patients with mtDNA
haplotypes that are very divergent indicates that the
A1555G mutation is the primary mtDNA factor con-
tributing to sensorineural deafness and that mitochon-
drial genetic background probably does not play a major
role in disease expression. This is further supported by
the haplotype distribution of the A1555G mutation
among affected Spanish families, which is similar to that
found in the general Spanish population, indicating that
there is no association between certain haplogroups and
maternally transmitted sensorineural deafness.
The A1555G mutation occurs in a highly conserved
region of the mitochondrial 12S rRNA, where the
mRNA is decoded. It has been postulated that the
A1555G mutation elongates the tRNA binding region
on the ribosome, with an adverse effect on the fidelity
of the translation of the mRNA, leading to hair-cell
death (Prezant et al. 1993). Both the strong association
between the A1555G mutation and sensorineural deaf-
ness and the lack of association with a specific haplo-
group strongly support the hypothesis that this mito-
chondrial change is the main cause of deafness.
Whereas the relationship between the A1555G mu-
tation and deafness after treatment with aminoglyco-
sides is absolute, only 17.7% of the deaf patients that
have this mutation received these antibiotics, and in sev-
eral cases deafness occurred before the introduction of
aminoglycosides into clinical practice, ∼50 years ago.
Thus, in seven of the families presented here and in the
Arab-Israeli pedigree (Prezant et al. 1993) and the Zai-
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Figure 4 Phylogenetic tree of mtDNA haplotypes of patients with sensorineural deafness and the A1555G mutation. This maximum-
parsimony tree includes five different haplotypes (1, 2, 64, 109, and 123) observed in the 10 unrelated patients from pedigrees S1–S10 (blackened
ovals) and the haplotypes described elsewhere for 237 European controls. The patients’ haplotypes are defined by the following mutations,
relative to the reference sequence (GenBank D38112): for S1 (haplogroup L), 3592h,10394c,13803e,16389g/16390b, and16517e;
for S2, S5, S7, S8, S9, and S10 (haplogroup H), 7025a and 16517e; for S3 (haplogroup H), 7025a; for S4 (haplogroup V), 4577q; and,
for S6 (haplogroup H), 7025a, 3846c/3849e, and 16517e. The tree was rooted by use of a Senegalese haplotype (African outgroup)
belonging to the African-specific haplogroup L (Torroni et al. 1994). “H,” “I,” “J,” “K,” “L,” “M,” “T,” “U,” “V,” “W,” and “X” indicate
major haplotype groupings (haplogroups), and the numbers associated with the lowercase letters indicate the sites for the restriction enzymes
that define the specific haplogroups. The restriction enzymes correspond to the following code: a, AluI; b, AvaII; c, DdeI; e, HaeIII; g, HinfI;
h, HpaI; k, RsaI; i, MspI; m, BamHI; n, HaeII; p, BstNI; q, NlaIII; and r, BfaI. The horizontal-branch lengths are proportional to the number
of mutational events that separate the haplotypes, with the exception of the 16517 HaeIII site. In the parsimony analysis, this hypervariable
site was assigned half the weight assigned to all other sites.
rean pedigree (Matthijs et al. 1996) there was no record
of treatment with aminoglycosides. Interestingly, only on
rare occasions, the A1555G mutation has been detected
in sporadic cases of aminoglycoside-induced deafness
(Fischel-Ghodsian et al. 1993, 1997; Hutchin et al.
1993). Therefore, treatment with these antibiotics
clearly is not indispensable for the development of hear-
ing loss associated with the A1555G mutation. Since it
has been shown that aminoglycosides cause hair-cell
death through enhancement of NMDA-receptor activity
(Basile et al. 1996), it is possible that aminoglycoside
ototoxicity and the A1555G mutation follow different
pathogenic pathways, which converge in hair-cell death
and the deafness phenotype.
Is the A1555G mutation alone enough to produce
hearing loss? Since not all the patients with the A1555G
mutation became deaf (50% penetrance by 30 years of
age, 88% penetrance by 65 years of age), other factors
must contribute to the development of deafness in the
affected subjects. With regard to the Arab-Israeli pedi-
gree, the action of a recessive modifying nuclear gene
on the A1555G effect had been suggested (Prezant et al.
1993) (also suggested for the Zairean pedigree; Matthijs
et al. 1996). One important difference between the
A1555G families described here and the Arab-Israeli
family is that hearing loss is mainly congenital in the
latter (Prezant et al. 1993) but is progressive and of later
onset in the Spanish families. It is likely that this reflects
either different modifying factors (genetic or environ-
mental) in the two genetic backgrounds or the presence
of a major nuclear gene in the Arab-Israeli family.
In conclusion, this study shows that the A1555G mu-
tation is a major factor in progressive inherited deafness
(with age-dependent penetrance) and that its penetrance
can be enhanced by treatment with aminoglycosides. We
also show that the A1555G mutation is much more com-
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mon (27.1% of all Spanish families with sensorineural
deafness, 55.9% of those with progressive deafness) than
was suspected previously. This finding suggests that this
mutation also might be common in affected families of
other European populations and that screening for the
A1555G mutation should be performed routinely in mo-
lecular-diagnostic centers. One of the reasons why, in
the past, the A1555G mutation had been rarely observed
in deaf families of European descent is probably due to
a bias, toward congenital cases, in the ascertainment of
families. Since the nonsyndromic-deafness families stud-
ied here were selected randomly and include both fam-
ilies with congenital deafness and those with progressive
deafness, it is likely that the figures previously published
for patterns of inheritance of hearing loss (mainly based
on congenital cases) are incorrect. The identification of
the A1555G mutation in families with deafness, the pre-
symptomatic detection of this mutation in maternally
related subjects, and the avoidance of aminoglycosides
by individuals who are positive for the A1555G muta-
tion should help in the prevention of deafness.
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